Related Experiment Video
Updated: Jun 28, 2025
07:24
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
1.7K
Hemoadsorption: consensus report of the 30th Acute Disease Quality Initiative workgroup
Rinaldo Bellomo1, Ghada Ankawi2, Sean M Bagshaw3
1Department of Critical Care, The University of Melbourne, Melbourne, Australia.
Summary
Hemoadsorption, an extracorporeal therapy, shows promise for various conditions but requires more research. While generally safe and effective at removing target molecules, its clinical benefits need further investigation in larger trials.
Area of Science:
- Biomedical Engineering
- Nephrology
- Critical Care Medicine
Background:
- Adsorption-based extracorporeal therapies have evolved over five decades.
- Recent advancements enhance biocompatibility and expand clinical applications.
- Physicochemical principles and clinical data support their use in diverse conditions.
Purpose of the Study:
- To review the current state of hemoadsorption therapies.
- To assess biocompatibility, safety, and efficacy.
- To identify future research directions and patient phenotypes.
Main Methods:
- Consensus conference convened by the Acute Disease Quality Initiative.
- Review of ex vivo, experimental, and clinical observations.
- Analysis of pilot and larger studies on hemoadsorption, including endotoxin-based approaches.
Main Results:
- Hemoadsorption demonstrates clinically acceptable short-term biocompatibility and safety.
- Technical feasibility and removal of target molecules are confirmed.
- Pilot studies suggest physiological benefits; endotoxin studies identify potential trial candidates.
Conclusions:
- Hemoadsorption is a novel intervention with confirmed in vivo molecule removal for intoxications.
- Concerns regarding harm and lack of benefit exist in some studies.
- Further research is essential due to limited data and experimental nature.
